Table of Contents
Trial overview
This interventional study is testing VG801 in people with biallelic ABCA4 mutation-associated retinal dystrophy[1]. The trial is designed to evaluate safety, tolerability, and early signs of benefit in vision and retinal structure[1].
The treatment is given by subretinal use, which means it is delivered under the retina, the light-sensing layer at the back of the eye[1].
Who can participate
The target population is patients with biallelic ABCA4 mutation-associated retinal dystrophy[1]. In simple terms, this means people who have inherited disease-causing changes in both copies of the ABCA4 gene[1].
The trial record provided does not list extra inclusion or exclusion rules, so the main known requirement is the specific inherited retinal disease[1].
What researchers are measuring
The main safety goals are to track the number, type, and severity of ocular and systemic adverse events, which means unwanted effects in the eye or elsewhere in the body[1]. The study also checks laboratory tests, including hematology, chemistry, and urinalysis[1].
Researchers are also measuring the humoral immune response against the AAV capsid, which means they are checking whether the body makes antibodies against the study vector[1]. Another safety measure is vector shedding, which looks for study material in blood, tears, and saliva until two negative samples are found[1].
Eye safety is followed with detailed ophthalmic exams, including slit lamp examination, optical coherence tomography (OCT), fundus photography, intraocular pressure checks, and fundus autofluorescence imaging[1]. These tests help researchers watch the structure and health of the retina and other parts of the eye[1].
Early efficacy measures include best corrected visual acuity (BCVA), contrast testing, retinal imaging, and mobility testing[1]. The study also measures retinal function with Goldmann kinetic visual fields, scotopic and photopic microperimetry, and full-field stimulus threshold testing[1].
In simple terms, the trial is asking whether VG801-1 can be given safely and whether it may help people see better, keep more retinal function, or move more safely in daily life[1].
Trial phase and size
This is a Phase 1/2 study[1]. Early-phase studies often start by looking closely at safety, then also explore whether there are early signs that the treatment could help[1].
The planned enrollment is 18 participants[1]. This is a small study, which fits an early research stage[1].
Study status
The trial status is Authorised[1]. The study record provided does not include results, so the information here is about the planned and ongoing research goals rather than final findings[1].
